ES has received 5 prior lines of therapy, with progression of disease documented on her most recent therapy with a rise in SPEP from 1.3 to 2.2 g/dL and in UPEP from 556 to 1342 mg/24 hours. The current clinical considerations include anemia, renal insufficiency, and PN grade 1 with pain.
ES has received 5 prior lines of therapy, with progression of disease documented on her most recent therapy with a rise in SPEP from 1.3 to 2.2 g/dL and in UPEP from 556 to 1342 mg/24 hours. The current clinical considerations include anemia, renal insufficiency, and PN grade 1 with pain.
